key: cord-0740223-gxqg140u
authors: O’Donnell, Andrew S.; Fazavana, Judicael; O’Donnell, James S.
title: The von Willebrand factor – ADAMTS‐13 axis in malaria
date: 2022-02-01
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12641
sha: fd7331a598b48e3bc7e53de69dbd231ea04185b1
doc_id: 740223
cord_uid: gxqg140u

Cerebral malaria (CM) continues to be associated with major morbidity and mortality, particularly in children aged <5 years in sub‐Saharan Africa. Although the biological mechanisms underpinning severe malaria pathophysiology remain incompletely understood, studies have shown that cytoadhesion of malaria‐infected erythrocytes to endothelial cells (ECs) within the cerebral microvasculature represents a key step in this process. Furthermore, these studies have also highlighted that marked EC activation, with secretion of Weibel‐Palade bodies (WPBs), occurs at a remarkably early stage following malaria infection. As a result, plasma levels of proteins normally stored within WPBs (including high‐molecular‐weight von Willebrand factor [VWF] multimers, VWF propeptide, and angiopoietin‐2) are significantly elevated. In this review, we provide an overview of recent studies that have identified novel roles through which these secreted WPB glycoproteins may directly facilitate malaria pathogenesis through a number of different platelet‐dependent and platelet‐independent pathways. Collectively, these emerging insights suggest that hemostatic dysfunction, and in particular disruption of the normal VWF–ADAMTS‐13 axis, may be of specific importance in triggering cerebral microangiopathy. Defining the molecular mechanisms involved may offer the opportunity to develop novel targeted therapeutic approaches, which are urgently needed as the mortality rate associated with CM remains in the order of 20%.

Von Willebrand factor (VWF) is a large multimeric plasma glycoprotein that plays key roles in normal hemostasis. 1,2 VWF binds to exposed collagen at sites of vascular injury and subsequently is able to tether and activate platelets. 2 In addition, VWF also functions as a carrier molecule for procoagulant factor VIII (FVIII), protecting it against early degradation. 3 Under normal conditions, VWF biosynthesis in vivo occurs only in endothelial cells (ECs) 4 and megakaryocytes. 5 VWF synthesized within ECs is either secreted into the plasma or stored within Weibel-Palade bodies (WPBs). 1 Following EC activation by a variety of different secretagogues, this stored VWF is actively secreted together with other WPB contents (including the VWF propeptide VWFpp and angiopoietin-2 [Ang-2]). Previous shear-based studies have demonstrated that ultra-large multimers (UL-VWF) secreted following EC activation becomes tethered on the cell surface to form elongated strings. 6 This unwound VWF is able to bind platelets, leading to the formation of long platelet-decorated VWF strings.

In normal plasma, formation of these strings is regulated by the zinc metalloprotease ADAMTS-13 which specifically cleaves VWF at the Tyr1605-MetM1606 bond within the A2 domain. 7 Consequently, VWF circulates as a series of heterogeneous multimers, with the larger multimers having significantly enhanced functional capacity. 1 The biological importance of ADAMTS-13 regulation of VWF multimer distribution is highlighted by the fact that inherited or acquired ADAMTS-13 deficiency triggers severe microangiopathic thrombosis in patients with thrombotic thrombocytopenic purpura (TTP). 8

Beyond its pivotal role in maintaining physiological hemostasis, recent data have demonstrated that VWF also plays important roles in inflammation. 9 In particular, VWF has been shown to bind to both granulocytes and macrophages. [10] [11] [12] A number of leukocyte receptors and VWF domains have been implicated in modulating these binding interactions (Figure 1 ). Specific leukocyte receptors reported to bind to VWF include the low-density lipoprotein receptorrelated protein-1; the scavenger receptor class A member I 13 ; the macrophage galactose-type lectin 14, 15 ; Siglec-5 16 and the Galectins-1 and -3. 17 In addition to this in vitro data, studies in animal models support the hypothesis that VWF plays direct roles in inflammation that may be platelet-dependent or -independent in nature. 18 For example, Petri et al. 19 demonstrated that pretreatment with anti-VWF blocking antibodies resulted in significantly attenuated leukocyte recruitment in murine models of thioglycollate-induced experimental peritonitis and keratinocyte-derived chemokine-stimulated cremaster muscle, respectively. Thus, VWF not only binds to leukocytes but can also modulate extravasation in a platelet-dependent manner.

Furthermore, Hillgruber et al. 20 showed that VWF-blocking antibodies also significantly reduced neutrophil recruitment in murine models of immune complex-mediated vasculitis and contact dermatitis.

Interestingly, in these cutaneous inflammation models, the ability of anti-VWF antibodies to inhibit leukocyte recruitment was shown to be platelet independent. Recent studies have demonstrated F I G U R E 1 VWF interacts with neutrophils and monocytes/macrophages to impact inflammation. Plasma VWF is able to interact with a variety of cell surface receptors expressed on macrophages and neutrophils and thereby plays a direct role in modulating proinflammatory responses. LRP1, low-density lipoprotein receptorrelated protein-1; MGL, macrophage galactose-type lectin; PSGL-1, P-selectin glycoprotein ligand-1; SR-A1, scavenger receptor class A member I. Image created with BioRender.com that VWF is also involved in both NETosis 21, 22 and complement activation. 23, 24 The concept that VWF is involved in inflammatory responses is further supported by data from murine sepsis experiments. In particular, significantly improved overall survival was observed in VWF −/− mice compared to wild-type controls in a cecal ligation puncture model. 25 Finally, recent studies have suggested that dysfunction of the VWF-ADAMTS-13 axis may also be important in the pathogenesis of the characteristic pulmonary microangiopathy seen in patients with severe COVID-19. 26-28

Markedly elevated VWF levels have been consistently reported in patients with malaria (Table 1) . [29] [30] [31] [32] Plasma VWF antigen (VWF:Ag) levels correlate with disease severity, so that the highest levels (in the range 300-500 IU/dL) are typically seen in children with cerebral malaria. (Table 1) . 30, 35 Collectively, these data suggest that severe malaria results in fulminant EC activation, with resultant WPB secretion leading to high plasma VWF concentrations ( Figure 2 ). 29 The mechanism(s) through which malaria infection causes such profound EC activation remain poorly defined.

However, studies performed in healthy volunteers infected with P falciparum showed that the increase in plasma VWF:Ag and VWFpp was present from an early stage following parasite infection when infected erythrocyte (IE) levels were <0.001%. 36 In contrast to the elevated plasma VWF levels observed in patients with severe malaria, studies suggest that ADAMTS-13 levels are significantly reduced (Table 1) . 31, 33, 34, 37 Furthermore, polymorphisms in ADAMTS-13 have been associated with malaria severity. 38 Importantly, however, reported reductions in ADAMTS-13 activity in severe malaria have been relatively modest, with plasma levels typically remaining above 30% of normal levels. Previous studies suggest that these ADAMTS-13 levels should be adequate to prevent accumulation of abnormal UL-VWF. 39 Nonetheless, the VWF:ADAMTS-13 ratio in children with CM is greatly increased. In addition to these quantitative variations, plasma levels of several putative ADAMTS-13 functional inhibitors (including interleukin-6 and free hemoglobin) are also significantly increased in malaria. 31, 37 Given these findings, it is perhaps unsurprising that abnormal UL-VWF (similar to those seen in TTP) have been reported in children with cerebral malaria (Table 1) . 32, 34, 37 Moreover, several studies have reported that the plasma VWF circulating in patients with severe malaria exists in an active conformation that allows shear-independent binding to platelets. 32,34,36 with Plasmodium berghei ANKA. Following infection, mice became progressively unwell, developing ECM features, with most mice dying after 6 to 7 days. In keeping with the findings observed in patients with severe malaria, P berghei infection was associated with a significant increase in murine plasma VWF:Ag levels. 48 Moreover, this marked increase in VWF levels was an early feature in the disease course, being observed before significant numbers of P berghei-infected erythrocytes were visible in the circulation. 48 Angiopoietin-2 (Ang-2) is another protein that is stored in WPBs and actively secreted following acute EC activation. 49 Significantly increased plasma Ang-2 levels were seen in C57BL/6J mice following inoculation with P berghei, which further supports the concept that EC activation and WPB secretion are consistent features in both human and murine CM. 48 Although plasma ADAMTS-13 levels were not significantly reduced in the murine ECM model, abnormal ultra-large multimers were again observed. Importantly, subsequent studies demonstrated that the clinical features of ECM progressed significantly more slowly and that overall survival was significantly longer in VWF −/− mice compared to wild-type controls. 48 More recently, Kraisin et al. 50 used this same ECM model but assessed the effect of using lower initial infecting doses of P berghei.

They confirmed that plasma VWF:Ag levels and Ang-2 levels were both significantly elevated following P berghei infection. In keeping with O'Regan et al., 48 ADAMTS-13 levels remained within the normal range in malaria-infected mice. 50 In this ECM model using reduced P berghei doses, a subtle reduction in clinical signs was again seen in VWF −/− mice in the late stages of the disease, but no significant improvement in overall survival was observed. 50 Cumulatively, these murine ECM data are consistent with human clinical findings in demonstrating that marked EC activation and WPB secretion represent hallmark features of CM. However, the findings also highlight the inherent limitations of the murine ECM model. 51 Thrombocytopenia is a common finding in patients with severe malaria. 52, 53 In addition, postmortem samples from children with fatal malaria have demonstrated accumulation of both platelets and leukocytes within occluded cerebral microvasculature. 54 Since VWF plays a key role in regulating platelet tethering, studies have investigated whether it may also be important in malaria-induced thrombocytopenia. However, data from the murine ECM experiments have demonstrated that thrombocytopenia is similar in VWF −/− mice compared to controls. 48, 50 Thus, it appears that thrombocytopenia in malaria is occurring through VWF-independent pathways. Similarly, VWF can also bind to leukocytes and has been implicated in playing a role in neutrophil extravasation. 10, 19, 20 Although cerebral leukocyte recruitment is also a hallmark feature in murine ECM, Kraisin et al. 50 showed that this process was not affected by VWF deficiency. Additional research studies will thus be required to elucidate the biological mechanisms through VWF influences the pathogenesis of cerebral malaria in vivo.

Examples of studies investigating VWF-ADAMTS-13 axis in human and murine malaria pathogenesis 

Malaria-associated acute respiratory distress syndrome (MA-ARDS) has been associated with both P falciparum and P vivax infections. 55 In the murine ECM model, VWF deficiency was associated with a partial protective effect. 48 Interestingly, in the MA-ARDS model, the opposite effect was observed, whereby overall survival was actually significantly reduced in VWF-/-mice compared to wild-type controls. 57 Subsequent studies demonstrated that this reduced survival was due to markedly increased PbNK65 parasitemia levels in the VWF-/-mice.

The biology through which VWF impacts parasitemia levels in this model remain unclear, but interestingly reticulocyte counts were also increased in VWF-/-animals. 57 Overall, this alternate murine model of severe malaria clearly further supports the hypothesis that the VWF-ADAMTS-13 axis is important in disease pathogenesis. Furthermore, it seems likely that VWF may have multifactorial effects that impact different stages in the malaria disease journey. 29,53

Postmortem studies performed on children with CM have reported significant platelet accumulation within the cerebral microvasculature. 54 Levels of thrombocytopenia have also been shown to correlate with increased severity of malaria infection, higher parasite density, and worse clinical outcomes. 52, 53 Accumulating recent data suggest that platelets impact malaria pathobiology through a number of different mechanisms. For example, platelets can play roles in facilitating IE clumping, 59 IE cytoadhesion to ECs, and IE sequestration. 6, 52 In F I G U R E 2 Marked EC activation with Weibel-Palade body exocytosis occurs at an early stage following malarial infection and facilitates IE cytoadhesion. Malaria-infected erythrocytes trigger marked early endothelial cell activation at a remarkably early stage following infection. This EC activation causes secondary exocytosis of Weibel-Palade bodies, leading to significant increases in plasma levels of VWF antigen, VWF propeptide, P-selectin, and angiopoietin-2. Plasma ADAMTS-13 activity is reduced, so that the VWF:ADAMTS-13 ratio is markedly increased. EC activation also leads to upregulated expression of adhesion molecules including P-selectin and ICAM-1, which serve to further promote IE sequestration. EC, endothelial cell; ICAM-1, intercellular adhesion molecule 1; IE, infected erythrocyte; UL-VWF, ultralarge von Willebrand factor multimers; VWF, von Willebrand factor; WPB, Weibel-Palade body. Image created with BioRender.com addition, platelets may contribute to EC activation and inflammatory responses in severe malaria infection. Besides these deleterious effects, several studies have reported an intriguing role for platelets in killing intraerythrocytic malaria parasites. 60, 61 This platelet-induced malaria killing process was most marked for P vivax but has also been observed for a number of different human malaria species (including P falciparum and P malariae). 62 The molecular mechanisms involved remain poorly understood but appear to require platelet-IE adhesion, as well as platelet CD36 and platelet factor-4. 61 Given the key role played by VWF in modulating platelet function under shear, further studies investigating the VWF-ADAMTS-13 axis in this context will be interesting. characterize circulating platelets in healthy volunteers experimentally infected with P falciparum (PB0759). 85 By day +10 following infection, a significant thrombocytopenia and a reduction in mean platelet volume were observed in malaria-infected subjects compared to controls. In addition, a reduction in platelet sialylation was also present in malaria cases. These findings are important given that terminal sialic acid expression plays a key role in protecting both platelets and plasma glycoproteins against premature clearance.

In summary, accumulating data over recent years have clearly demonstrated that both platelets and acute EC activation play critical roles in the pathogenesis underlying severe malaria. These effects have been observed in both patients infected with malaria and a variety of different murine models. Elucidating the precise molecular mechanisms involved, and how the importance of these mechanisms varies through the course of malarial illness, will require further studies. In view of the huge global morbidity and mortality that continue to be associated with severe malaria, these studies are urgently needed to address an important unmet clinical need. Improved understanding of the mechanisms involved may facilitate the development of novel treatment strategies.

JSO was supported by a National Children's Research Centre Project Award (C/18/1).

JSO has served on the speaker's bureau for Baxter, Bayer, Novo Nordisk, Boehringer Ingelheim, Leo Pharma, Takeda, and

Octapharma. He has also served on the advisory boards of Baxter, Bayer, Octapharma, CSL Behring, Daiichi Sankyo, Boehringer

Ingelheim, Takeda, and Pfizer. He has also received research grant funding awards from Baxter, Bayer, Pfizer, Shire, Takeda, and Novo

Nordisk.

All authors drafted the first version of the manuscript and critically reviewed the final manuscript.

https://orcid.org/0000-0003-0309-3313

von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends

Von Willebrand's disease

Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia

Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization

Biosynthesis of von Willebrand protein by human megakaryocytes

Rapid activation of endothelial cells enables Plasmodium falciparum adhesion to platelet-decorated von Willebrand factor strings

Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor

Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura

von Willebrand factor and inflammation

P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor

Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo

N-linked glycans within the A2 domain of von Willebrand factor modulate macrophagemediated clearance

Macrophage scavenger receptor SR-AI contributes to the clearance of von Willebrand factor

A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance

Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin mediated clearance

Factor VIII and von Willebrand factor are ligands for the carbohydrate-receptor Siglec-5

Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor

Targeting von Willebrand factormediated inflammation

von Willebrand factor promotes leukocyte extravasation

Blocking von Willebrand factor for treatment of cutaneous inflammation

von Willebrand factor directly interacts with DNA from neutrophil extracellular traps

VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice

Von Willebrand factor interacts with surface-bound C1q and induces platelet rolling

Afshar-Kharghan V. von Willebrand factor is a cofactor in complement regulation

Willebrand factor is a major determinant of ADAMTS-13 decrease during mouse sepsis induced by cecum ligation and puncture

Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19

The ADAMTS13-von Willebrand factor axis in COVID-19 patients

Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation

Emerging roles for hemostatic dysfunction in malaria pathogenesis

von Willebrand factor propeptide in malaria: evidence of acute endothelial cell activation

Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria

Endothelial activation, haemostasis and thrombosis biomarkers in Ugandan children with severe malaria participating in a clinical trial

Severe malaria is associated with a deficiency of von Willebrand factor cleaving protease, ADAMTS13

ADAMTS13 deficiency with elevated levels of ultra-large and active von Willebrand factor in P. falciparum and P. vivax malaria

Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective case-control study

Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria

Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition

Association of ADAMTS13 polymorphism with cerebral malaria

Variations among normal individuals in the cleavage of endothelial-derived ultra-large von Willebrand factor under flow

Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment

Pathogenesis of cerebral malaria-inflammation and cytoadherence

Molecules on the surface of the Plasmodium falciparum infected erythrocyte and their role in malaria pathogenesis and immune evasion

A human 88-kD membrane glycoprotein (CD36) functions in vitro as a receptor for a cytoadherence ligand on Plasmodium falciparum-infected erythrocytes

An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration

Severe malaria is associated with parasite binding to endothelial protein C receptor

Differential roles of CD36, ICAM-1, and P-selectin in Plasmodium falciparum cytoadherence in vivo

Malaria: modification of the red blood cell and consequences in the human host

A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria

Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study

von Willebrand factor increases in experimental cerebral malaria but is not essential for late-stage pathogenesis in mice

The role of animal models for research on severe malaria

Understanding platelets in malaria infection

Platelets in malaria pathogenesis

Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria

A prospective comparative study of knowlesi, falciparum, and vivax malaria in Sabah, Malaysia: high proportion with severe disease from Plasmodium knowlesi and Plasmodium vivax but no mortality with early referral and artesunate therapy

Respiratory manifestations of malaria

Willebrand factor in experimental malaria-associated acute respiratory distress syndrome

Plasmin cleaves Von Willebrand factor at K1491-R1492 in the A1-A2 linker region in a shear-and glycan-dependent manner in vitro

Platelet-mediated clumping of Plasmodium falciparum-infected erythrocytes is a common adhesive phenotype and is associated with severe malaria

Platelets kill intraerythrocytic malarial parasites and mediate survival to infection

Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum

Platelets kill circulating parasites of all major Plasmodium species in human malaria

Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities

Factor VIII and von Willebrand factor-too sweet for their own good

The relationship between ABO blood group, von Willebrand factor, and primary hemostasis

Platelet von Willebrand factor-structure, function and biological importance

Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis

The effect of ABO blood group on the diagnosis of von Willebrand disease

ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?

Evidence for a major effect of ABO locus on factor VIII level

von Willebrand factor clearance -biological mechanisms and clinical significance

A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor

Role of A and B blood group antigens in the expression of adhesive activity of von Willebrand factor

Blood group alters platelet binding kinetics to von Willebrand factor and consequently platelet function

An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13

Expression of terminal alpha2-6-linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13

ABO blood group phenotypes and Plasmodium falciparum malaria: unlocking a pivotal mechanism

Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children

Parasite histones are toxic to brain endothelium and link blood barrier breakdown and thrombosis in cerebral malaria

The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling

The ABO blood group system and Plasmodium falciparum malaria

Endothelial cells orchestrate COVID-19 coagulopathy

Pulmonary immunothrombosis in COVID-19 ARDS pathogenesis

More on 'Association between ABO blood groups and risk of SARS-CoV-2 pneumonia

Platelets show a distinct response in a controlled human malaria infection (CHMI) model